On July 22, Samsung Bioepis announced that it has received marketing approval by the FDA for its eculizumab biosimilar Epysqli®. The vowel-challenged brand name, which also has an interesting nonproprietary suffix (eculizumab-aagh), is the second approved biosimilar for the reference product Solaris®. The approval for this C5 complement protein inhibitor covers the following indications: Samsung … Continue reading Samsung Bioepis’ Epysqli Is the Second Eculizumab Biosimilar Approved by the FDA